Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company located in Berkeley Heights, New Jersey. The company focuses on developing innovative cancer medicines that target cell cycle, transcriptional regulation, and mitosis biology. Noteworthy efforts include the evaluation of fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor, aimed at treating solid tumors and hematological malignancies. Cyclacel's commitment to advancing cancer treatment positions it as a key player in the pharmaceutical industry.
